|
|
Article: Biotica grants Wyeth $195M rapamycin license.(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- October 16, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biotica Technology, a privately-held UK biotechnology company, has signed an exclusive research collaboration and license agreement with US drug major Wyeth, focused on the discovery, development and commercialization of novel rapamycin analogs that target diseases in multiple, undisclosed therapeutic areas. Rapamycin was discovered by Wyeth and, while originally developed as an antifungal agent, it is also a potent immunosuppressant with antiproliferative properties.
Biotica has granted Wyeth worldwide rights to its most advanced drug candidates, a portfolio of additional rapamycin analogs, and the technology to discover new ...